COSMO PHARMACEUTICALS N.V.
Cosmo N.V. — known as Cosmo Pharmaceuticals N.V. until the company’s name change in April 2026 — is a naamloze vennootschap (public limited company) incorporated under the laws of the Netherlands, with its registered office in Amsterdam and a Dutch Chamber of Commerce (KVK) registration number of 65617738. The company also maintains an operating office in Dublin, Ireland, at One North Dock, 91/94 North Wall Quay, Dublin 1, D01 H7V7, which is separately recorded with the Irish Companies Registration Office (CRO) as an external company under registration number 908460, effective 21 March 2016. This Irish CRO filing reflects the registration of Cosmo’s Irish place of business and is not a separate Irish incorporation: the company’s place of incorporation remains the Netherlands.
Cosmo N.V. is a life sciences company that develops, manufactures and commercialises pharmaceutical products and AI-enabled medical devices, principally for gastroenterology, dermatology and connected health technology. Its portfolio includes GI Genius, an artificial-intelligence system used to assist detection of colorectal lesions during endoscopy, the acne treatment Winlevi, and mesalamine-based therapies for ulcerative colitis marketed as Lialda, Mezavant and Mesavancol, among other products. The group also carries out contract manufacturing of pharmaceutical drug-delivery technologies.
The company’s shares are listed on the SIX Swiss Exchange, trading under the ticker CMHC (previously COPN prior to the 2026 rename). For the six months ended 30 June 2025, Cosmo reported consolidated group revenue of approximately EUR51.7 million, an increase of around 18% compared with the same period a year earlier. The group employed approximately 365 people as of the most recent publicly reported headcount.
Cosmo N.V. traces its origins to Cosmo S.p.A., an Italian pharmaceutical manufacturer founded in 1997, from which the listed group structure was established ahead of its 2007 SIX Swiss Exchange listing. The Irish CRO registration (908460) that appears on this profile corresponds specifically to the company’s registered external-company presence in Dublin, where core commercial, technical and regulatory functions of the group are based.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
5
Shareholders of Cosmo N.V.
Cosmo N.V. is listed on the SIX Swiss Exchange (ticker CMHC, formerly COPN), and its disclosed shareholder base consists of institutional and fund investors reported through significant-shareholding notifications rather than a complete shareholder register. Internal disclosure data records twelve reportable holdings as of 31 December 2024, of which the largest include iShares Core MSCI EAFE ETF at approximately 5.46% (60,416 ordinary shares), the Vanguard FTSE All-World ex-US Small-Cap strategy at approximately 2.84% (31,347 shares), the iShares MSCI EAFE Small-Cap ETF at approximately 2.73% (30,164 shares), the Old Westbury Small & Mid Cap Strategies Fund at approximately 4.54% (50,166 shares), and the Vanguard European Stock Index fund at approximately 1.90% (21,021 shares). All disclosed holdings are denominated in Swiss francs and relate to ordinary shares. No shareholder in the reviewed disclosures is reported as a natural person.
Ultimate beneficial ownership
No verified ultimate beneficial owner is identified in the reviewed disclosures. The largest disclosed holders are collective investment funds and index-tracking vehicles, which do not on their own establish an individual UBO, and no ownership chain permitting a calculated effective percentage for a natural person is available.
Data availability
Disclosure for Cosmo N.V. is major shareholders only: as a SIX-listed company it publishes significant-shareholder notifications above the applicable disclosure threshold, but not a complete register of all shareholders. The most recent holdings data available for this review is dated 31 December 2024.
Sources
- Companies Registration Office (CRO), Ireland — https://www.cro.ie (retrieved 2026-09-18)
- SIX Swiss Exchange significant shareholder disclosures, as reflected in Zavia’s underlying shareholder dataset (holdings dated 2024-12-31, retrieved 2026-09-18)
Registry feed — rows exactly as filed with Companies Registration Office (CRO), including entries the profile above does not cover.
| Shareholder | Type | Holding | Source Document |
|---|---|---|---|
| iShares Core MSCI EAFE ETF | 5.5% | Companies Registration Office (CRO) | |
| Old Westbury Small & Mid Cap Strategies Fund | 4.5% | Companies Registration Office (CRO) | |
| VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Small-Cap | 2.8% | Companies Registration Office (CRO) | |
| iShares Trust-iShares MSCI EAFE Small-Cap ETF | 2.7% | Companies Registration Office (CRO) | |
| Vanguard International Stock Index-Vanguard European Stock Index | 1.9% | Companies Registration Office (CRO) |
Officers
16
Directors and officers of Cosmo N.V.
Sixteen officers are disclosed for Cosmo N.V. in total, of which detailed records are available for five in the reviewed dataset, all marked as active with no resignation recorded. Current roles reviewed include Chief Scientific Officer (Luigi Longo), Qualified Person & Technical Director (Davide Malavasi), SVP of Manufacturing, Service and Security (Giulio Evangelisti), President of Cosmo Intelligent Medical Devices (Ngo Dinh Nhan), and Founder & Non-Executive Director (Mauro Severino Ajani). The source data does not include appointment or resignation dates for any of these individuals, so tenure and recent changes in office cannot be determined from it.
Data availability
Officer information for this Irish CRO filing is partial: work status (active) and job title are recorded, but appointment dates, resignation dates and nationality are not disclosed in the reviewed source. Correspondence-address countries are recorded for some officers (Germany, Ireland and Italy among those reviewed) but these reflect only a correspondence or service address, not the individual’s nationality or country of residence, and have not been used to infer either.
Sources
- Companies Registration Office (CRO), Ireland — https://www.cro.ie (retrieved 2026-09-18)
Registry feed — rows exactly as filed with Companies Registration Office (CRO), including entries the profile above does not cover.
Group Structure
Group structure of Cosmo N.V.
Cosmo N.V. is a single legal entity incorporated in the Netherlands (KVK company number 65617738, registered office Amsterdam). It is separately registered in Ireland with the Companies Registration Office as an external company under number 908460 for its Dublin place of business; this Irish filing represents the same legal entity’s branch registration, not a distinct Irish parent or subsidiary, and it is not presented as such below. No further verified ultimate parent above Cosmo N.V. was identified.
A verified direct shareholding was confirmed for Cosmo Technologies Limited (Ireland, CRO 395100), an Irish-incorporated private company limited by shares, wholesale distributor of pharmaceutical goods, in which Cosmo N.V. (under its predecessor name Cosmo Pharmaceuticals N.V.) is recorded as a direct company shareholder; the exact current shareholding percentage was not confirmed in this review. Additional group-linked entities — Cassiopea S.p.A. (Italy), Cosmo Artificial Intelligence – AI Limited (Ireland, CRO 558186) and its Italian entity Linkverse S.r.l., Cosmo Foundry Limited (Ireland, CRO 813832) and its Italian entity Cosmo Foundry S.r.l., and Aries Pharmaceuticals Limited (Ireland, CRO 585496) and its US entity Aries Pharmaceuticals, Inc. — appear in Zavia’s underlying corporate-linkage data but were not independently re-confirmed against each entity’s own registry filing in this review, and ownership percentages are not disclosed for any of them.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| Cosmo Technologies Limited | Ireland | 395100 | Direct subsidiary (shareholding confirmed) | Ownership percentage not disclosed | Active | 2026-09-18 |
| Cassiopea S.p.A. | Italy | IT08338370961 | Possible relationship (not independently re-verified) | Ownership percentage not disclosed | Unconfirmed | 2026-09-18 |
| Cosmo Artificial Intelligence – AI Limited | Ireland | 558186 | Possible relationship (not independently re-verified) | Ownership percentage not disclosed | Unconfirmed | 2026-09-18 |
| Linkverse S.r.l. | Italy | IT09836921008 | Possible indirect relationship (not independently re-verified) | Ownership percentage not disclosed | Unconfirmed | 2026-09-18 |
| Cosmo Foundry Limited | Ireland | 813832 | Possible relationship (not independently re-verified) | Ownership percentage not disclosed | Unconfirmed | 2026-09-18 |
| Cosmo Foundry S.r.l. | Italy | IT14776750961 | Possible indirect relationship (not independently re-verified) | Ownership percentage not disclosed | Unconfirmed | 2026-09-18 |
| Aries Pharmaceuticals Limited | Ireland | 585496 | Possible relationship (not independently re-verified) | Ownership percentage not disclosed | Unconfirmed | 2026-09-18 |
| Aries Pharmaceuticals, Inc. | United States | CA 0450160008 | Possible indirect relationship (not independently re-verified) | Ownership percentage not disclosed | Unconfirmed | 2026-09-18 |
Data availability
Group-structure information for Cosmo N.V. is partial: the entity’s own Dutch incorporation and Irish external-company registration are confirmed and are clarified above as the same legal entity rather than separate group members, and one subsidiary shareholding (Cosmo Technologies Limited) was independently confirmed. The remaining linked entities are drawn from internal corporate-linkage data and have not each been individually re-confirmed against their own registry filings in this review.
Sources
- Companies Registration Office (CRO), Ireland — https://www.cro.ie (retrieved 2026-09-18)
- OpenCorporates, Cosmo Technologies Limited (IE 395100) — https://opencorporates.com/companies/ie/395100 (retrieved 2026-09-18)
Cosmo N.V.
Netherlands
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does COSMO PHARMACEUTICALS N.V. do?
Cosmo N.V. (formerly Cosmo Pharmaceuticals N.V.) is a Dutch-incorporated life sciences company developing pharmaceuticals and AI-enabled medical devices for gastroenterology, dermatology and health tech, including the GI Genius AI colorectal-lesion detection system.
Who owns COSMO PHARMACEUTICALS N.V.?
Major disclosed shareholders as of 31 December 2024 are institutional funds, including iShares Core MSCI EAFE ETF (~5.46%), Old Westbury Small & Mid Cap Strategies Fund (~4.54%) and Vanguard index funds; this is a major-shareholders-only disclosure, not a complete register.
Who is COSMO PHARMACEUTICALS N.V.'s UBO (Ultimate Beneficial Owner)?
No individual ultimate beneficial owner is identified in the reviewed disclosures; the largest holders are institutional investment funds.
What is COSMO PHARMACEUTICALS N.V.'s company registration number?
COSMO PHARMACEUTICALS N.V.'s registration number is IE908460, filed with Companies Registration Office (CRO) in Ireland. Its current status on the register is active.
Is COSMO PHARMACEUTICALS N.V. still an active company?
COSMO PHARMACEUTICALS N.V.'s status on Companies Registration Office (CRO) is listed as active.
When was COSMO PHARMACEUTICALS N.V. incorporated?
COSMO PHARMACEUTICALS N.V. was incorporated on 21 March 2016, according to Companies Registration Office (CRO).
What is COSMO PHARMACEUTICALS N.V.'s registered address?
The registered address on file for COSMO PHARMACEUTICALS N.V. is DUBLIN 2,DUBLIN, Ireland.
What is COSMO PHARMACEUTICALS N.V.'s revenue?
Consolidated group revenue of approximately EUR51.7 million for the six months ended 30 June 2025, up around 18% year-on-year.
Is COSMO PHARMACEUTICALS N.V. listed on a stock exchange?
Listed on the SIX Swiss Exchange under ticker CMHC (formerly COPN), following the rename from Cosmo Pharmaceuticals N.V. to Cosmo N.V. in April 2026.
Who are the officers/directors of COSMO PHARMACEUTICALS N.V.?
16 officers are disclosed, all recorded as active with no appointment or resignation dates in the source; reviewed roles include Chief Scientific Officer and Qualified Person & Technical Director.
Does COSMO PHARMACEUTICALS N.V. have a parent company or subsidiaries?
Cosmo N.V. is incorporated in the Netherlands (KVK 65617738) and separately registered in Ireland as an external company (CRO 908460) for its Dublin office; a verified subsidiary is Cosmo Technologies Limited (Ireland, CRO 395100).
Can Zavia monitor changes to COSMO PHARMACEUTICALS N.V.'s ownership over time?
This profile reflects a point-in-time snapshot from Companies Registration Office (CRO). Zavia's monitoring API can track changes to COSMO PHARMACEUTICALS N.V.'s registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access COSMO PHARMACEUTICALS N.V.'s data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including Ireland, so records like COSMO PHARMACEUTICALS N.V.'s registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Companies Registration Office (CRO) and was last synced on 18 September 2026.